Ensysce Biosciences (ENSCW) EPS (Weighted Average and Diluted) (2020 - 2025)
Ensysce Biosciences (ENSCW) reported EPS (Weighted Average and Diluted) of -$0.56 for Q4 2025, up 80.89% year-over-year from -$0.31 in Q4 2024, and up 56.59% quarter-over-quarter from -$1.29 in Q3 2025.
Ensysce Biosciences (ENSCW) EPS (Weighted Average and Diluted) (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.56 in Q4 2025.
- EPS (Weighted Average and Diluted) for Q4 2025 came in at -$0.56, up 80.89% year-over-year; the trailing twelve-month figure through Dec 2025 was -$4.03 (up 70.13% YoY), and the FY2025 annual result was -$3.98, up 65.24% from the prior year.
- EPS (Weighted Average and Diluted) climbed to -$0.56 in Q4 2025 per ENSCW's latest filing, from -$1.29 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $1.48 in Q4 2022 and troughed at -$67.08 in Q4 2023.
- A 5-year average of -$12.13 and a median of -$1.29 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 421.74% in 2022 and fell as far as 8573.24% in 2022.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.46 in 2021, then surged by 421.74% to $1.48 in 2022, then tumbled by 4632.43% to -$67.08 in 2023, then soared by 95.63% to -$2.93 in 2024, then jumped by 80.89% to -$0.56 in 2025.
- Business Quant data shows ENSCW's EPS (Weighted Average and Diluted) at -$0.56 in Q4 2025, -$1.29 in Q3 2025, and -$0.79 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Ensysce Biosciences | - | - | - | -0.56 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.56 |
| Sep 30, 2025 | -1.29 |
| Jun 30, 2025 | -0.79 |
| Mar 31, 2025 | -1.39 |
| Dec 31, 2024 | -2.93 |
| Sep 30, 2024 | 1.00 |
| Jun 30, 2024 | -3.35 |
| Mar 31, 2024 | -8.21 |
| Dec 31, 2023 | -67.08 |
| Sep 30, 2023 | -0.87 |
| Jun 30, 2023 | -0.98 |
| Mar 31, 2023 | -2.08 |
| Dec 31, 2022 | 1.48 |
| Sep 30, 2022 | -61.58 |
| Jun 30, 2022 | -56.49 |
| Dec 31, 2021 | -0.46 |
| Sep 30, 2021 | -0.71 |
| Dec 31, 2020 | 0.01 |
| Sep 30, 2020 | 0.09 |